Glioblastoma Multiforme Pipeline

View All

glioma-vs-glioblastoma-therapeutics-space
Glioma vs. Glioblastoma Therapeutics Space: Unveiling the Battlefront

Glioma and glioblastoma are both types of brain tumors, but they differ significantly in their characteristics and prognosis. Glioma is a broad term that encompasses tumors originating from glial cells, which are supportive cells in the brain. These tumors can vary in grade and aggressiveness, with some growing slo...

Find More

Glioblastoma-Multiforme-Market-Analysis-and-Pipeline-Insights
Glioblastoma Multiforme Market: Emerging Pipeline Therapies To Keep A Keen Eye On

The present Glioblastoma multiforme (GBM) market has several unmet needs. Poor prognosis, 10-15 months median survival rate, no curative treatment to the patients, limited treatment options, drug resistance, incapability of therapies to cross BBB (blood-brain-barrier), intratumor heterogeneity, and a high mortality...

Find More